Last reviewed · How we verify

NCT05397444

Handgrip Strength (HGS) With HGS Asymmetry Are Associated With All-cause Mortality and Hospital Readmissions

Completed Last updated 31 May 2022
What this trial tests

trial testing No intervention in Gastric Cancer in 342 participants. Completed in 30 March 2022.

Timeline
1 March 2021
Primary endpoint
30 March 2022
30 March 2022

Quick facts

Lead sponsorNanjing Medical University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment342
Start date1 March 2021
Primary completion30 March 2022
Estimated completion30 March 2022
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Nanjing Medical University

Who can join

Eligibility, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Adding the handgrip strength (HGS) asymmetry to the existing measurements of low HGS may improve the assessment of muscle function.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

Other Nanjing Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05397444.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing